Ark Therapeutics Group Plc has appointed David Venables to the position of executive director, manufacturing services, to oversee the company’s viral manufacturing operation in Finland. He will report to Martyn Williams, the chief executive. Ark develops gene-based medicines which are administered using viral vectors. Dr Venables was previously chief operating officer of Intercell USA Inc, based in Maryland. He holds a PhD in mammalian cell fermentation from Surrey University in the UK and worked at Invitrogen Corp and BioReliance Europe before joining Intercell in 2007.
Copyright 2012 Evernow Publishing Ltd